Jody Chastain, Ritedose CEO

No­vo Hold­ings picks up in­jecta­bles CD­MO in push for sin­gle-use man­u­fac­tur­ing tech

For 25 years, Rite­dose has been a CD­MO that’s pro­vid­ed ster­ile, asep­tic pro­duc­tion of sin­gle-dose med­ica­tion for more than 8 bil­lion dos­es. No­vo Hold­ings has tak­en no­tice, ac­quir­ing the Co­lum­bia, GA-based com­pa­ny from AG­IC Cap­i­tal and Hu­man­well.

“The in­vest­ment in Rite­dose is per­fect­ly aligned with our deep ex­per­tise in phar­ma ser­vices. We see myr­i­ad op­por­tu­ni­ties to have an im­pact at Rite­dose,” No­vo’s head of prin­ci­pal in­vest­ments Ab­hi­jeet Lele said in a state­ment. “We are al­so par­tic­u­lar­ly ex­cit­ed to be at the van­guard of in­creas­ing vac­cine avail­abil­i­ty through the use of blow-fill-seal in­jectable tech­nol­o­gy.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.